Buy or sell TP Therapeutics stock pre IPO via an EquityZen fund

EquityZen is a marketplace for shares of proven pre IPO tech companies

TP Therapeutics Stock

TP Therapeutics is a structure-based drug design pharmaceutical company

Founded

2013

Notable Investors

Headquarters

San Diego CA, US

Total Funding

$144M

About TP Therapeutics Stock

TP Therapeutics, Inc. is a structure-based drug design pharmaceutical company founded by Dr. J. Jean Cui, the lead inventor of Pfizer's Xalkori(TM) (generic name: crizotinib), the precision oncology drug for non-small cell lung cancer (NSCLC). Xalkori(TM) was approved by US Food and Drug Administration on August 26th, 2011.

0

Funding History

January 2014$1.4M
March 2016$18.0M
May 2017$45.0M
October 2018$80.0M

Management

Founder & CSO

J. Jean Cui

Senior Vice President, Clinical Operations and Regulatory Affairs

John K.C. Lim

CEO

Athena Countouriotis

Co-founder, Chairman, President, and CEO

Y. Peter Li

Vice President of Pre-Clinical Development

Jeffrey P. Whitten

0

Other Companies

Logo
Emulate

Emulate, Inc. is a private company focused on commercializing Organs-on-Chips.

Logo
Inscripta, Inc

Inscripta is a gene editing technology company.

Logo
Jounce Therapeutics

Jounce Therapeutics is developing cancer immune-therapies to harness the immune system to attack cancerous cells and tumors.

Logo
ViaCyte

Preclinical Therapeutic Company

EquityZen does not have an affiliation with, formal relationship with, or endorsement from TP Therapeutics or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 70K+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo

Logo